MARKET

MDXXF

MDXXF

Pharmala Biotech
OTCMQB
0.110
NaN%
Closed 09:30 05/20 EDT
OPEN
--
PREV CLOSE
0.110
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.540
52 WEEK LOW
0.032
MARKET CAP
11.96M
P/E (TTM)
-9.6579
1D
5D
1M
3M
1Y
5Y
1D
PharmAla signs term sheet licensing exclusive US rights to ALA-002 to Jupiter Neurosciences
PUBT · 13h ago
Jupiter Neurosciences Signs Term Sheet For Exclusive U.S. Rights To PharmAla Biotech Holdings MDMA Drug Candidate ALA-002 In Deal Worth Over $100M Including Milestones And Royalties
Benzinga · 13h ago
JUPITER NEUROSCIENCES INC - TO BUY EXCLUSIVE U.S. RIGHTS TO ALA-002 FROM PHARMALA BIOTECH
Reuters · 14h ago
JUPITER NEUROSCIENCES INC: SECURES $100M TERM SHEET FOR EXCLUSIVE U.S. RIGHTS TO ALA-002
Reuters · 14h ago
Jupiter Neurosciences agrees to pay $3.33 million for exclusive US rights to PharmAla’s ALA-002
PUBT · 14h ago
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million
Barchart · 18h ago
Weekly Report: what happened at MDXXF last week (0511-0515)?
Weekly Report · 2d ago
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings
TipRanks · 6d ago
More
About MDXXF
PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.

Webull offers Pharmala Biotech Holdings Inc stock information, including OTCMQB: MDXXF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDXXF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDXXF stock methods without spending real money on the virtual paper trading platform.